https://doi.org/10.55788/646add85
The findings of the global, randomised, double-blind, placebo-controlled ADMIRE-CD II trial (NCT03279081) were shared by Dr Laura Raffals (Mayo Clinic, MN, USA) [1]. A total of 568 participants were randomised 1:1 to receive either a single dose of darvadstrocel or a placebo. Preconditioning involved curettage, seton placement, and closure of internal openings before administering the treatment. The primary endpoint was combined remission at 24 weeks, defined as the closure of all treated external openings that were draining at baseline. Secondary endpoints included combined remission at 52 weeks, clinical remission at 24 and 52 weeks, and the time to clinical remission at 24 weeks.
At 24 weeks, combined remission was achieved by 48.8% in the darvadstrocel group and 46.3% in the placebo group, with a non-significant difference (Δ2.4%; 95% CI -5.8 to 10.6; P=0.571). Combined remission rates at 52 weeks remained non-significant between darvadstrocel and placebo groups (39.7% vs 41%; Δ1.3%; 95% CI -6.8 to 9.3; P=0.757). The authors, however, emphasised that the placebo response rate was unexpectedly high, particularly after the onset of the COVID-19 pandemic.
The safety profile showed that darvadstrocel was well tolerated, with safety patterns comparable with placebo.
“Treatment of complex perianal fistulas with a single dose of darvadstrocel showed no statistically significant or clinically meaningful differences in our key efficacy endpoints when compared with placebo, noting that the placebo group also received fistula preconditioning. An unexpectedly high response rate was observed in the placebo group,” Dr Raffals concluded.
- Raffals L, et al. Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s disease: results from the global ADMIRE-CD II phase 3 study. 761, DDW 2024, 18–21 May, Washington DC, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise Next Article
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD »
« PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise Next Article
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD »
Table of Contents: DDW 2024
Featured articles
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
Eosinophilic Oesophagitis Treatments and Outcomes
Mepolizumab improves the histologic severity of eosinophilic oesophagitis
Budesonide demonstrates efficacy in eosinophilic oesophagitis
Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis
Quality-of-life assessment in children with eosinophilic oesophagitis
Gut-Brain Axis and Neurological Disorders
Gut permeability and neuroinflammation linked in Parkinson’s disease
Cardiovascular and Metabolic Health Innovations
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
Inflammatory Bowel Disease Therapies
GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
QUASAR maintenance study: Guselkumab effective and safe for UC
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD
ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas
Advances in Endoscopy and Screening Techniques
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions
Liver and Biliary Tract Diseases Updates
Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC
Nutritional consultation boosts nutritional status in patients with alcohol-associated hepatitis
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
Acalculous cholecystitis as a risk factor for gallbladder perforation: insights from a 10-year retrospective study
Other Gastrointestinal Diseases
STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure
COX-2 inhibitors show promise in reducing severity of acute pancreatitis
Hormone-containing therapies may increase the risk of IBS and functional dyspepsia
Related Articles
October 23, 2019
Half of common medications wreak havoc on gut microbiome
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com